Inaphaea Evaluation and Commercial Use Agreement

Inaphaea is pleased to confirm the execution of an Evaluation and Commercial Use agreement ("Agreement") with UK based Screenin3d Limited ("Screenin3D") to provide Inaphaea's Patient Derived Cells ("PDC") for evaluation and commercial use in Screenin3D's state-of-the-art UpScale3Dlab-on-a-chip technology with associated image analysis software. The Agreement initially focusses on establishment of three Triple Negative Breast Cancer in-vitro 3D tumour model which will then be offered for commercial services by Screenin3D and Inaphaea. Additional PDCs across Inaphaea's range of 66 cancer types can be added at any time.

Inaphaea will be entitled to an upfront fee of £10,000 per PDC cell line upon commercialisation of the models. Screenin3D have an option to buy the commercial rights in relation to the PDCs and support future drug development. Both companies have also agreed to co-market their respective services. The Agreement is for a period of 12 months initially and may be extended in writing by mutual agreement.

Mark Eccleston, CEO of ValiRx commented "We are continuously looking for commercial partners to accelerate Inaphaea's capabilities and market access. Screenin3D's UpScale3Dlab-on-a-chip platform and established customer base is a perfect example of technology and commercial synergy for Inaphaea's biobank of Patient Derived Cells. We look forward to the development of the triple negative breast cancer models which will also be used to support ValiRx's cytolytic peptide program through our partially owned subsidiary, Cytolytix. The data sets generated, alongside standard of care drugs, will be used to support commercialisation of the new UpScale3D PDC models and we look forward to publishing the results with ScreenIn3D in due course."

Michele Zagnoni, CEO of Screenin3d Limited, commented "We are excited to collaborate with Inaphaea to expand commercial opportunities for accelerating drug discovery and translational research. Combining our patented UpScale3D lab-on-a-chip technology with Inaphaea's biobank of Patient Derived Cells, this partnership will offer novel and powerful preclinical services in oncology and women's health, enabling us to facilitate large numbers of drug tests on very small quantities of predictive human samples of disease."

Engage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investorhub here: https://valirx.com/s/cc8ef3

Subscribe to our news alert service: https://valirx.com/s/f298d1